Founded in Zhangjiang Pharmaceutical Valley, Pudong, Shanghai, it relies on the anti-tumor research team of the Institute of Materia Medica, Chinese Academy of Sciences

Move into the Caohejing Economic Park in Shanghai, establish a 700-square-meter R&D pilot laboratory, and embark on the path of industrialization

The patent related to morpholine compounds has obtained a domestic application number

A new domestic patent has been applied for the purification method of camptothecin compounds

Received 1 certification for high-tech achievement transformation project in Shanghai

Jointly submit the DMF documents for docetaxel and irinotecan hydrochloride

Establish a joint laboratory for industry-university-research cooperation with Shanghai University of Engineering Science, and undertake the "Shanghai Science and Technology Special Commissioner" project

Obtained 3 newly applied invention patents

On May 26th, the factory in Taizhou, Zhejiang officially commenced production, and on June 16th, the first batch of 200 kilograms of qualified products was produced

Received the second prize for scientific and technological progress in Songjiang District for the year 2008-2009

Obtained 1 authorized invention patent and newly applied for 2 invention patents

Undertake the Innovation Fund Project for Small and Medium-sized Enterprises in Songjiang District

Obtained ISO9001 quality system management certification

Obtained the certification of high-tech enterprise in Shanghai

We have been granted 3 invention patents and have newly applied for 2 invention patents

Undertake the Shanghai SME Innovation Fund Project

Move into the new Fei Enterprise Home, and restructure the Marketing Department, R&D Department, and Quality Department

Received 2 recognitions for high-tech achievement transformation projects in Shanghai

Obtained 1 authorized invention patent and newly applied for 2 invention patents

The office has moved into the new Fei Enterprise Home C3, with the original C7 being transformed into a research and development and quality center

One new invention patent application

Awarded the title of "Specialized, Fine, Unique, and Innovative Enterprise" in Shanghai, and has been interviewed and reported by "Shanghai Business Daily" and "Jiefang Daily"

We have established a strategic partnership with Chongqing Southwest Pharmaceutical Factory No. 2 to jointly build a production platform. We have successfully achieved the production of advanced pharmaceutical intermediates under the GMP system, with comprehensive upgrades in product quality and production capacity

Recognized as a pilot enterprise for patent work in Shanghai

Awarded the title of "Specialized, Fine, Unique and Innovative Enterprise" in Shanghai

Pass the review of high-tech enterprises in Shanghai

One invention patent has been granted, and four new invention patents have been applied for

Holding Anhui Changtai Chemical Co., Ltd., we have a production base that operates independently, boasts well-equipped facilities, and possesses comprehensive safety and environmental qualifications

Obtained 2 authorized invention patents and newly applied for 3 invention patents

Wholly-owned acquisition of Anhui Biocompounds Chemicals Co., Ltd (formerly Anhui Changtai Chemical Co., Ltd.)

Establish Anhui Bocompounds Pharmaceutical Co., Ltd

Received 1 authorized invention patent and newly applied for 7 invention patents

Shanghai Little Giant Technology Cultivation Enterprise Passes Acceptance Inspection

Shanghai Expert Workstation is officially established

We have been granted 3 invention patents and have newly applied for 4 invention patents

Pass the review of high-tech enterprises in Shanghai

The second batch of enterprises in Anhui Province involved in the "Three Major and One Innovation" program for major emerging industries

Jianfeng Pharmaceutical, a subsidiary of Zhejiang Jianfeng Group, has invested in Shanghai Beika, holding a 55% controlling stake

Wholly-owned acquisition of Anhui Bocompounds Pharmaceutical Co., Ltd (Anhui Zhongwang Pharmaceutical Co., Ltd.)

Establish the Small Molecule Targeted Drug Research Institute

Pass the acceptance of the Little Giant (Cultivation) scientific research project

Obtained 2 authorized invention patents and newly applied for 5 invention patents

Certified by ISO9001/14001/18001 quality management system

Received 4 authorized invention patents and newly applied for 4 invention patents

The industry-university-research innovation project has passed the acceptance inspection

Obtain a drug production license

The project titled "Quality Improvement and Industrialization Optimization of Erlotinib Hydrochloride and Its Advanced Intermediates" was awarded the Bronze Prize for Excellent Invention at the 31st Shanghai Excellent Invention Selection Competition

Pass the review of high-tech enterprises in Shanghai

Obtained 2 authorized invention patents and newly applied for 2 invention patents

The project titled "Quality Improvement and Industrialization Optimization of Erlotinib Hydrochloride and Its Advanced Intermediates" was awarded the Silver Prize for Excellent Invention at the 32nd Shanghai Excellent Invention Selection Competition

Establish a Green Fluorinated Pharmaceutical Engineering Technology Research Center with Shanghai Institute of Technology

Pass the re-evaluation of ISO9001/14001/18001 quality management system certification

Obtained one certification of Shanghai High-tech Achievement Transformation Project

Obtained 1 authorized invention patent and newly applied for 2 invention patents

In April, we obtained ISO9001/14001/45001 quality management system certification

In July, it was successfully selected as a national-level "Little Giant" enterprise specializing in precision, specialty, uniqueness, and novelty

In December, the project titled "Process Development and Industrialization Optimization of Antiviral Drug Intermediate Kalonate Anhydride" was awarded the Silver Prize for Excellent Invention at the 34th Shanghai Excellent Invention Selection Competition

Awarded as "Advanced Enterprise in Technological Innovation" for the year 2022

Obtained 3 authorized invention patents and newly applied for 1 invention patent

In March, the review of specialized, refined, unique, and innovative small and medium-sized enterprises in Shanghai was completed

In April, we passed the ISO9001/14001/45001 quality management system audits

In July, it was awarded the "Top 100 Science and Technology Innovation Drivers" among private enterprises in the Yangtze River Delta G60 Science and Technology Innovation Corridor

In November, we passed the re-certification of high-tech enterprises in Shanghai

2 new invention patents applied

Complete the supervision and audit of ISO9001/14001/45001 quality management systems

2 new invention patents applied

Certified by ISO9001/14001/18001 quality management system

Pass the review of "small giant" enterprises that are specialized, refined, unique, and innovative

1 new invention patents applied